Trevena Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

TrevenaDie Umsatzerlöse des Unternehmens werden voraussichtlich um 11.7% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 2.1% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 24.1% pro Jahr wachsen.

Wichtige Informationen

2.1%

Wachstumsrate der Gewinne

24.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	-11.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:TRVN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-32	N/A	N/A	1
12/31/2025	9	-25	N/A	N/A	2
12/31/2024	0	-32	N/A	N/A	2
3/31/2024	3	-40	-32	-32	N/A
12/31/2023	3	-40	-33	-33	N/A
9/30/2023	3	-31	-38	-38	N/A
6/30/2023	3	-38	-39	-39	N/A
3/31/2023	0	-45	-44	-44	N/A
12/31/2022	0	-54	-52	-51	N/A
9/30/2022	0	-61	-53	-53	N/A
6/30/2022	0	-59	-54	-54	N/A
3/31/2022	0	-58	-54	-54	N/A
12/31/2021	1	-52	-50	-50	N/A
9/30/2021	1	-50	-45	-45	N/A
6/30/2021	3	-41	-36	-36	N/A
3/31/2021	3	-33	-30	-30	N/A
12/31/2020	3	-29	-21	-21	N/A
9/30/2020	3	-24	-21	-21	N/A
6/30/2020	0	-27	-25	-25	N/A
3/31/2020	0	-25	-22	-22	N/A
12/31/2019	0	-25	-24	-24	N/A
9/30/2019	0	-26	-22	-23	N/A
6/30/2019	3	-22	-20	-20	N/A
3/31/2019	6	-27	-23	-23	N/A
12/31/2018	6	-31	-26	-25	N/A
9/30/2018	6	-38	-32	-31	N/A
6/30/2018	3	-49	-41	-39	N/A
3/31/2018	N/A	-60	-56	-52	N/A
12/31/2017	N/A	-72	N/A	-71	N/A
9/30/2017	N/A	-93	N/A	-87	N/A
6/30/2017	N/A	-107	N/A	-100	N/A
3/31/2017	2	-106	N/A	-100	N/A
12/31/2016	4	-103	N/A	-92	N/A
9/30/2016	6	-82	N/A	-76	N/A
6/30/2016	8	-63	N/A	-63	N/A
3/31/2016	8	-55	N/A	-55	N/A
12/31/2015	6	-51	N/A	-40	N/A
9/30/2015	4	-48	N/A	-41	N/A
6/30/2015	3	-53	N/A	-40	N/A
3/31/2015	1	-53	N/A	-40	N/A
12/31/2014	N/A	-50	N/A	-40	N/A
9/30/2014	N/A	-43	N/A	-37	N/A
6/30/2014	N/A	-37	N/A	-33	N/A
3/31/2014	0	-30	N/A	-28	N/A
12/31/2013	0	-24	N/A	-24	N/A
9/30/2013	0	-20	N/A	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRVNDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-11.7% pro Jahr).

Hohe Wachstumseinnahmen: TRVNDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-11.7% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRVN in 3 Jahren voraussichtlich hoch sein wird

Trevena Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Consensus EPS estimates fall by 28%, revenue upgraded

Consensus revenue estimates increase by 725%

Price target decreased by 39% to US$17.00

Price target decreased to US$28.67

Consensus forecasts updated

Recent updates

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena Investor Presentation - Slideshow

Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial